Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study

Haematologica. 2004 Oct;89(10):1275-6.

Abstract

This study is a long-term follow-up analysis evaluating clinical outcome of patients with mantle-cell lymphoma treated by the sequential CHOP and DHAP chemotherapy followed by autografting. The median overall survival of 81 months (95% CI, 66-not reached) and the median event free survival of 51 months (95% CI, 43-not reached) confirm the improvement in outcome obtained by such protocol.

Publication types

  • Clinical Trial
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cisplatin / administration & dosage
  • Combined Modality Therapy
  • Cyclophosphamide / administration & dosage
  • Cytarabine / administration & dosage
  • Dexamethasone / administration & dosage
  • Disease Progression
  • Disease-Free Survival
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Follow-Up Studies
  • Humans
  • Life Tables
  • Lymphoma, Mantle-Cell / drug therapy*
  • Lymphoma, Mantle-Cell / mortality
  • Lymphoma, Mantle-Cell / surgery
  • Peripheral Blood Stem Cell Transplantation*
  • Prednisone / administration & dosage
  • Prognosis
  • Prospective Studies
  • Salvage Therapy
  • Survival Analysis
  • Transplantation, Autologous
  • Vincristine / administration & dosage
  • Whole-Body Irradiation

Substances

  • Cytarabine
  • Vincristine
  • Etoposide
  • Dexamethasone
  • Doxorubicin
  • Cyclophosphamide
  • Cisplatin
  • Prednisone

Supplementary concepts

  • CHOP protocol
  • DHAP protocol